Multiple Myeloma Clinical Trials

A listing of 196 Multiple Myeloma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Multiple Myeloma

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 196 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Clinical Study

Recruiting

We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.

Conditions:

Cough

Chronic Cough

Asthma

Allergic Asthma

Sinusitis

Learn More

Featured Trial

Healthy Volunteer Trials

Recruiting

Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!

Conditions:

Healthy

Learn More

Featured Trial

Healthy Volunteer Clinical Studies

Recruiting

Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.

Conditions:

Healthy

Healthy Volunteers

Learn More

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

NCT01838512

Recruiting

The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.

Gender:

All

Ages:

18 years and above

Trial Updated:

02/16/2023

Locations: Local Institution, Birmingham, Alabama +191 locations

Local Institution, Birmingham, Alabama

Local Institution - 0021, Birmingham, Alabama

Local Institution - 0013, Muscle Shoals, Alabama

Local Institute, Goodyear, Arizona

Local Institution, Anaheim, California

Pacific Cancer Madical Center, Anaheim, California

East Valley Hematology And Oncology Medical Group, Burbank, California

Local Institution, Corona, California

The Oncology Institute Of Hope And Innovation, Downey, California

Compassionate Cancer Care Medical Group, Fountain Valley, California

Local Institute, Los Angeles, California

Local Institute, Santa Rosa, California

St Joseph Heritage Healthcare, Santa Rosa, California

Local Institution - 0057, Washington, District of Columbia

Florida Cancer Specialists & Research Institute, Brooksville, Florida

Local Institution, Brooksville, Florida

Michael and Dianne Bienes Cancer Center, Fort Lauderdale, Florida

Local Institution - 0017, Jacksonville, Florida

Local Institution, Jacksonville, Florida

Summit Cancer Care, Savannah, Georgia

Local Institute, Valdosta, Georgia

Pearlman Cancer Center, Valdosta, Georgia

Local Institution, Skokie, Illinois

SIU Simmons Cancer Institute, Springfield, Illinois

Local Institution - 0012, Urbana, Illinois

St. Vincent Anderson Regional Hospital, Anderson, Indiana

Indiana Blood and Marrow Transplantation LLC, Indianapolis, Indiana

Local Institution, Indianapolis, Indiana

Local Institution - 0061, Des Moines, Iowa

Local Institute, Sioux City, Iowa

Local Institution - 0018, Sioux City, Iowa

Local Institution - 0062, Lexington, Kentucky

Local Institution - 0064, London, Kentucky

Local Institute, Louisville, Kentucky

Norton Cancer Institute, Louisville, Kentucky

Cancer Center of Acadiana at Lafayette General Health, Lafayette, Louisiana

Local Institution, Lafayette, Louisiana

Local Institution - 0009, Shreveport, Louisiana

Local Institution, Shreveport, Louisiana

Local Institution, Minneapolis, Minnesota

Minnesota Oncology Hematology, P.A., Woodbury, Minnesota

Local Institution - 0059, Jackson, Mississippi

Local Institute, Southaven, Mississippi

Local Institute, Kansas City, Missouri

Research Medical Center, Kansas City, Missouri

Montana Cancer Institute Foundation, Missoula, Missouri

Local Institute, Saint Joseph, Missouri

Local Institution - 0015, Saint Louis, Missouri

Local Institution, Saint Louis, Missouri

Local Institution, Springfield, Missouri

Mercy Medical Research Institute, Springfield, Missouri

Local Institute, Missoula, Montana

Local Institution - 0060, Lincoln, Nebraska

Local Institute, Omaha, Nebraska

Oncology Hematology West, P.C., Omaha, Nebraska

Bms Clinical Research Center, Does Not Exist, New Jersey

Stony Brook University Hospital, Stony Brook, New York

Local Institute, Cary, North Carolina

Waverly Hematology Oncology, Cary, North Carolina

Gaston Hematology & Oncology, Gastonia, North Carolina

Local Institution, Gastonia, North Carolina

Gabrail Cancer Center Research, Canton, Ohio

Local Institute, Canton, Ohio

Local Institute, Cleveland, Ohio

Local Institution - 0019, Cleveland, Ohio

Local Institute, Tulsa, Oklahoma

Tulsa Cancer Institute PLLC, Tulsa, Oklahoma

Local Institute, Portland, Oregon

Local Institute, Pottstown, Pennsylvania

Pottstown Hospital Tower Health - Oncology, Pottstown, Pennsylvania

Charleston Oncology, Charleston, South Carolina

Local Institute, Charleston, South Carolina

Local Institute, Knoxville, Tennessee

University of Tennessee Medical Center, Knoxville, Tennessee

Baptist Cancer Center, Memphis, Tennessee

Local Institution, Memphis, Tennessee

Local Institute, Amarillo, Texas

Local Institution - 0029, Amarillo, Texas

Local Institution - 0063, Bryan, Texas

Local Institute, Corpus Christi, Texas

Local Institute, Dallas, Texas

Dallas Presbyterian Hospital - Texas Oncology PA, Dallas, Texas

Local Institute, Dallas, Texas

UT Southwestern Medical Center, Dallas, Texas

Texas Oncology-Garland, Garland, Texas

Cancer Care Centers Of South Texas, San Antonio, Texas

Local Institute, San Antonio, Texas

Local Institute, Sherman, Texas

Local Institution - 0028, Sherman, Texas

Local Institute, Seattle, Washington

VA Puget Sound Health Care System, Seattle, Washington

Cancer Care Northwest, Spokane, Washington

Local Institute, Spokane, Washington

Local Institute, Yakima, Washington

Yakima Valley Memorial Hospital, Yakima, Washington

Local Institution - 0065, Toronto, Ontario

Local Institute, Toronto, Ontario

Local Institution - 0066, Toronto, Ontario

Local Institute, Weston, Ontario

Local Institute, Blois, Not set

Local Institution - 0106, Cannes Cedex, Not set

Local Institution - 0099, Chalon sur Saone, Not set

Local Institute, Chalon sur Saone, Not set

Local Institute, La Roche sur Yon, Not set

Local Institution - 0100, La Roche-sur-yon Cedex 9, Not set

Local Institution - 0104, Limoges, Not set

Local Institute, Limoges, Not set

Local Institution - 0105, Meaux, Not set

Local Institute, Meaux, Not set

Local Institution - 0102, Nantes, Not set

Local Institute, Nantes, Not set

Local Institution - 0101, Perigueux, Not set

Local Institute, Rennes, Not set

Local Institution - 0103, Rennes, Not set

Local Institute, Heidelberg, Baden-Württemberg

Local Institute, Hamm, Nordrhein-Westfalen

Local Institute, Aschaffenburg, Not set

Local Institution - 0072, Aschaffenburg, Not set

Local Institute, Berlin, Not set

Local Institution - 0068, Berlin, Not set

Local Institution - 0081, Bielefeld, Not set

Local Institution, Bochum, Not set

Local Institute, Dresden, Not set

Local Institution - 0069, Dresden, Not set

Local Institution - 0082, Dresden, Not set

Local Institution - 0077, Frankfurt-oder, Not set

Local Institution - 0084, Gelsenkirchen, Not set

Local Institution - 0089, Goslar, Not set

Local Institution - 0070, Hamm, Not set

Local Institution - 0071, Heidelberg, Not set

Local Institution - 0088, Kiel, Not set

Local Institution - 0087, Köln, Not set

Local Institution - 0076, Ludwigsburg, Not set

Local Institute, Magdeburg, Not set

Local Institution - 0067, Magdeburg, Not set

Local Institution - 0073, Muenchen, Not set

Local Institution - 0079, Mutlangen, Not set

Local Institute, München, Not set

Local Institution - 0080, Oldenburg, Not set

Local Institution - 0075, Reutlingen, Not set

Local Institution - 0074, Rostock, Not set

Local Institution - 0086, Rostock, Not set

Local Institute, Rostock, Not set

Local Institution - 0078, Traunstein, Not set

Local Institution - 0085, Wiesbaden, Not set

Local Institute, Pesaro, Pesaro E Urbino

Local Institute, Ancona, Not set

Local Institution - 0108, Ancona, Not set

Local Institute, Ancona, Not set

Local Institution - 0119, Cagliari, Not set

Local Institute, Cagliari, Not set

Local Institution - 0111, Firenze, Not set

Local Institute, Firenze, Not set

Local Institute, Lecce, Not set

Local Institution - 0113, Lecce, Not set

Local Institution - 0124, Messina, Not set

Local Institution - 0120, Messina, Not set

Local Institute, Milano, Not set

Local Institution - 0116, Milano, Not set

Local Institute, Napoli, Not set

Local Institution - 0114, Napoli, Not set

Local Institution - 0115, Pesaro, Not set

Local Institution - 0121, Pescara, Not set

Local Institute, Roma, Not set

Local Institution - 0109, Roma, Not set

Local Institution - 0110, Roma, Not set

Local Institution - 0118, Roma, Not set

Local Institution, Roma, Not set

Local Institution - 0122, San Giovanni Rotondo (FG), Not set

Local Institution - 0107, Terni, Not set

Local Institute, Terni, Not set

Local Institute, Torino, Not set

Local Institution - 0112, Torino, Not set

Local Institute, Vicenza, Not set

Local Institution - 0117, Vicenza, Not set

Local Institute, Truro, Cornwall

Local Institution - 0098, Harrow, Not set

Local Institute, Leeds, Not set

Local Institution - 0092, Leeds, Not set

Local Institution - 0091, Liverpool, Not set

Local Institution, Liverpool, Not set

Local Institution - 0097, Manchester, Not set

Local Institute, Nottingham, Not set

Local Institution - 0095, Nottingham, Not set

Local Institute, Stafford, Not set

Local Institution - 0096, Stafford, Not set

Local Institute, Swansea, Not set

Local Institution - 0093, Swansea, Not set

Local Institution - 0094, Truro, Not set

Conditions: Multiple Myeloma

Learn More ›

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

NCT05007418

Recruiting

This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

Gender:

All

Ages:

18 years and above

Trial Updated:

01/12/2023

Locations: UC Irvine, Orange, California +2 locations

Conditions: Multiple Myeloma

Learn More ›

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

NCT03570983

Recruiting

The work proposed herein aims to provide the first prospective, randomized comparative efficacy data between Melphalan and BEAM treatment regimen in the Multiple Myeloma (MM) patient population. The risk of such a study is deemed reasonable and ethical since: a) previous works have closely examined the safety and toxicity of the BEAM regimen and the doses to be delivered in this protocol are well below the toxicity levels; b) phase III trials of BEAM have provided reasonable data regarding the e... Read More

Gender:

All

Ages:

Between 18 years and 70 years

Trial Updated:

06/21/2022

Locations: Swedish Cancer Institute, Seattle, Washington

Conditions: Multiple Myeloma

Learn More ›

MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey

NCT04727294

Recruiting

The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus. The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, hea... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

08/02/2021

Locations: HealthTree.org (Online), Lehi, Utah

Conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Coronavirus

Learn More ›